Cargando…

Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects

Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical-stage therapeutic antibodies target the spike receptor binding domain (RBD), but variants often have multiple mutations in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lusvarghi, Sabrina, Wang, Wei, Herrup, Rachel, Neerukonda, Sabari Nath, Vassell, Russell, Bentley, Lisa, Eakin, Ann E., Erlandson, Karl J., Weiss, Carol D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Vaccines and Antiviral Agents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754225/ https://www.ncbi.nlm.nih.gov/pubmed/34668774 http://dx.doi.org/10.1128/JVI.01110-21

Ejemplares similares

Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies
por: Wang, Wei, et al.
Publicado: (2018)

Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins
por: Marjuki, Henju, et al.
Publicado: (2016)

A Single Amino Acid Substitution at Residue 218 of Hemagglutinin Improves the Growth of Influenza A(H7N9) Candidate Vaccine Viruses
por: Li, Xing, et al.
Publicado: (2019)

Insight into Vaccine Development for Alphacoronaviruses Based on Structural and Immunological Analyses of Spike Proteins
por: Shi, Yuejun, et al.
Publicado: (2021)

Novel Epitopes of the Influenza Virus N1 Neuraminidase Targeted by Human Monoclonal Antibodies
por: Kirkpatrick Roubidoux, Ericka, et al.
Publicado: (2022)

Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein
por: Chen, Yuliu, et al.
Publicado: (2022)

Establishment of a Monoclonal Antibody against Human NTCP That Blocks Hepatitis B Virus Infection
por: Takemori, Toshitada, et al.
Publicado: (2022)

Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein
por: van Haaren, M. M., et al.
Publicado: (2021)

Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants
por: Ishimaru, Hanako, et al.
Publicado: (2023)

Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays
por: Yu, Jingyou, et al.
Publicado: (2021)

SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses
por: Carnell, George W., et al.
Publicado: (2021)

Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity
por: Jensen, Jaime L., et al.
Publicado: (2023)

Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein
por: Choi, Jung-ah, et al.
Publicado: (2020)

HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis
por: Wills, Saintedym, et al.
Publicado: (2018)

Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies
por: Vigil, Adam, et al.
Publicado: (2020)

Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans
por: Rijal, Pramila, et al.
Publicado: (2020)

Somatic Hypermutation and Framework Mutations of Variable Region Contribute to Anti-Zika Virus-Specific Monoclonal Antibody Binding and Function
por: Tsuji, Isamu, et al.
Publicado: (2022)

Antigenic Characterization of Human Monoclonal Antibodies for Therapeutic Use against H7N9 Avian Influenza Virus
por: Chang, Pengxiang, et al.
Publicado: (2022)

Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
por: Ma, Huan, et al.
Publicado: (2021)

A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance
por: Urbanowicz, Richard A., et al.
Publicado: (2016)

SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity
por: Neerukonda, Sabari Nath, et al.
Publicado: (2021)

Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer
por: Zhan, Wuqiang, et al.
Publicado: (2022)

A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity
por: Rubio, Adonis A., et al.
Publicado: (2021)

Recombinant Infectious Bronchitis Viruses Expressing Chimeric Spike Glycoproteins Induce Partial Protective Immunity against Homologous Challenge despite Limited Replication In Vivo
por: Ellis, Samantha, et al.
Publicado: (2018)

Engineering a Live Attenuated Porcine Epidemic Diarrhea Virus Vaccine Candidate via Inactivation of the Viral 2'-O-Methyltransferase and the Endocytosis Signal of the Spike Protein
por: Hou, Yixuan, et al.
Publicado: (2019)

Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease
por: Deschambault, Yvon, et al.
Publicado: (2022)

COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice
por: García-Arriaza, Juan, et al.
Publicado: (2021)

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants
por: Ferrari, Mathieu, et al.
Publicado: (2021)

Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo
por: Weston, Stuart, et al.
Publicado: (2020)

Analysis of B Cell Receptor Repertoires Reveals Key Signatures of the Systemic B Cell Response after SARS-CoV-2 Infection
por: Zhang, Yudi, et al.
Publicado: (2022)

4-Octyl itaconate reduces influenza A replication by targeting the nuclear export protein CRM1
por: Ribó-Molina, Pau, et al.
Publicado: (2023)

Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques
por: Devasundaram, Santhi, et al.
Publicado: (2020)

Evaluation of in vitro antiviral activity of SARS-CoV-2 M(pro) inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions
por: Tong, Xiao, et al.
Publicado: (2023)

Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity
por: Johnson, Bryan A., et al.
Publicado: (2019)

Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens
por: Schiffner, Torben, et al.
Publicado: (2015)

The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization
por: Schorcht, Anna, et al.
Publicado: (2022)

Influenza A(H7N9) Virus Acquires Resistance-Related Neuraminidase I222T Substitution When Infected Mallards Are Exposed to Low Levels of Oseltamivir in Water
por: Gillman, Anna, et al.
Publicado: (2015)

Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells
por: Ternette, Nicola, et al.
Publicado: (2015)

VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV
por: van de Water, Sandra G. P., et al.
Publicado: (2015)

Molecular Basis of the Divergent Immunogenicity of Two Pediatric Tick-Borne Encephalitis Virus Vaccines
por: Beck, Yvonne, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_usf0rq55cip4acc4bdfh3hovu0